BUSINESS CONCEPT
WntResearch is a biotech company whose focus is to develop new drugs that increase cancer survival by inhibiting the spread of metastases.
The company’s main drug candidate is Foxy-5.
VISION
Cancer patients should no longer have to go through metastases.
MISSION
WntResearch’s mission is to counteract the metastatic process by developing and providing new cancer therapies.
STRATEGIES
Development company
WntResearch is a pharmaceutical drug development company. The company itself does not generate any revenue during the development period but invests available funds for possible future earnings on its drug candidates, primarily Foxy-5.
Focus on Foxy-5
The company will focus on continued development and clinical studies of the main drug candidate Foxy-5.
Continued development of the drug candidate Box-5 and the development of new drug candidates will be paused.
Patent
The company’s continued patent strategy is primarily based on further broadening patent protection for Foxy-5 based on a new manufacturing method and from data generated in the NeoFox study.
Business development
The company is to develop a clear clinical development plan for market registration in colorectal cancer stage III, and additionally explore the potential for Foxy-5 to be used in other cancer diseases – creating the best possible conditions for a partnership or licensing arrangement for Foxy-5.
Organisation
The company has a small organization for greater cost efficiency where specialist competencies such as CROs are contracted.
Clinical trial Phase 2 study NeoFox
In light of the reported unexpectedly rapid positive observations with Foxy-5, the study plan for the phase 2 study NeoFox has been revised. The change involves introducing new outcome measures, resulting in a significantly shorter time to results in the study.
Financing
The company will continuously evaluate its future capital needs.